BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 15098018)

  • 1. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome.
    Yu Q; König R; Pillai S; Chiles K; Kearney M; Palmer S; Richman D; Coffin JM; Landau NR
    Nat Struct Mol Biol; 2004 May; 11(5):435-42. PubMed ID: 15098018
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asymmetric Modification of Hepatitis B Virus (HBV) Genomes by an Endogenous Cytidine Deaminase inside HBV Cores Informs a Model of Reverse Transcription.
    Nair S; Zlotnick A
    J Virol; 2018 May; 92(10):. PubMed ID: 29491156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. APOBEC3G is a single-stranded DNA cytidine deaminase and functions independently of HIV reverse transcriptase.
    Suspène R; Sommer P; Henry M; Ferris S; Guétard D; Pochet S; Chester A; Navaratnam N; Wain-Hobson S; Vartanian JP
    Nucleic Acids Res; 2004; 32(8):2421-9. PubMed ID: 15121899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity.
    Newman EN; Holmes RK; Craig HM; Klein KC; Lingappa JR; Malim MH; Sheehy AM
    Curr Biol; 2005 Jan; 15(2):166-70. PubMed ID: 15668174
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs.
    Svarovskaia ES; Xu H; Mbisa JL; Barr R; Gorelick RJ; Ono A; Freed EO; Hu WS; Pathak VK
    J Biol Chem; 2004 Aug; 279(34):35822-8. PubMed ID: 15210704
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletion.
    Xu H; Svarovskaia ES; Barr R; Zhang Y; Khan MA; Strebel K; Pathak VK
    Proc Natl Acad Sci U S A; 2004 Apr; 101(15):5652-7. PubMed ID: 15054139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOBEC3G DNA deaminase acts processively 3' --> 5' on single-stranded DNA.
    Chelico L; Pham P; Calabrese P; Goodman MF
    Nat Struct Mol Biol; 2006 May; 13(5):392-9. PubMed ID: 16622407
    [TBL] [Abstract][Full Text] [Related]  

  • 8. APOBEC3G & HTLV-1: inhibition without deamination.
    Strebel K
    Retrovirology; 2005 May; 2():37. PubMed ID: 15921532
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA deamination mediates innate immunity to retroviral infection.
    Harris RS; Bishop KN; Sheehy AM; Craig HM; Petersen-Mahrt SK; Watt IN; Neuberger MS; Malim MH
    Cell; 2003 Jun; 113(6):803-9. PubMed ID: 12809610
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts.
    Mangeat B; Turelli P; Caron G; Friedli M; Perrin L; Trono D
    Nature; 2003 Jul; 424(6944):99-103. PubMed ID: 12808466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary function of the two catalytic domains of APOBEC3G.
    Navarro F; Bollman B; Chen H; König R; Yu Q; Chiles K; Landau NR
    Virology; 2005 Mar; 333(2):374-86. PubMed ID: 15721369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation.
    Luo K; Wang T; Liu B; Tian C; Xiao Z; Kappes J; Yu XF
    J Virol; 2007 Jul; 81(13):7238-48. PubMed ID: 17428847
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutational comparison of the single-domained APOBEC3C and double-domained APOBEC3F/G anti-retroviral cytidine deaminases provides insight into their DNA target site specificities.
    Langlois MA; Beale RC; Conticello SG; Neuberger MS
    Nucleic Acids Res; 2005; 33(6):1913-23. PubMed ID: 15809227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new approach to an AIDS vaccine: creating antibodies to HIV vif will enable apobec3G to turn HIV-infection into a benign problem.
    Jeffrey Fessel W
    Med Hypotheses; 2005; 64(2):261-3. PubMed ID: 15607551
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cellular APOBEC3G restricts HIV-1 infection in resting CD4+ T cells.
    Chiu YL; Soros VB; Kreisberg JF; Stopak K; Yonemoto W; Greene WC
    Nature; 2005 May; 435(7038):108-14. PubMed ID: 15829920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of tRNA₃(Lys)-primed reverse transcription by human APOBEC3G during human immunodeficiency virus type 1 replication.
    Guo F; Cen S; Niu M; Saadatmand J; Kleiman L
    J Virol; 2006 Dec; 80(23):11710-22. PubMed ID: 16971427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. APOBEC3G ubiquitination by Nedd4-1 favors its packaging into HIV-1 particles.
    Dussart S; Douaisi M; Courcoul M; Bessou G; Vigne R; Decroly E
    J Mol Biol; 2005 Jan; 345(3):547-58. PubMed ID: 15581898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New insights into the role of Vif in HIV-1 replication.
    Schröfelbauer B; Yu Q; Landau NR
    AIDS Rev; 2004; 6(1):34-9. PubMed ID: 15168739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APOBEC3G targets human T-cell leukemia virus type 1.
    Sasada A; Takaori-Kondo A; Shirakawa K; Kobayashi M; Abudu A; Hishizawa M; Imada K; Tanaka Y; Uchiyama T
    Retrovirology; 2005 May; 2():32. PubMed ID: 15943885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protecting APOBEC3G: a potential new target for HIV drug discovery.
    Stopak K; Greene WC
    Curr Opin Investig Drugs; 2005 Feb; 6(2):141-7. PubMed ID: 15751736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.